Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2018-05-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2018.04.016PMID 29685684PMCID PMC5937995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protease-Activated Receptor 1

  2020cited by this paper
• PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury

  2018cited by this paper
• Targeting PAR1: Now What?

  2017cited by this paper
• Challenges and Opportunities in Protease-Activated Receptor Drug Development.

  2017cited by this paper
• Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding

  2017cited by this paper
• Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.

  2017cited by this paper
• Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.

  2016cited by this paper
• Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease

  2016cited by this paper
• Identification of an active metabolite of PAR-1 antagonist RWJ-58259 and synthesis of analogues to enhance its metabolic stability.

  2016cited by this paper
• EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice.

  2015cited by this paper
• Activated protein C: biased for translation.

  2015cited by this paper
• Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar.

  2015cited by this paper
• Protease-activated receptor signalling by coagulation proteases in endothelial cells

  2014cited by this paper
• Activated protein C based therapeutic strategies in chronic diseases

  2014cited by this paper
• Biased signalling and proteinase‐activated receptors (PARs): targeting inflammatory disease

  2014cited by this paper
• Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway

  2013cited by this paper
• Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3.

  2013cited by this paper
• Neutrophil Proteinase 3 Acts on Protease-Activated Receptor-2 to Enhance Vascular Endothelial Cell Barrier Function

  2013cited by this paper
• High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar

  2012cited by this paper
• Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes.

  2012cited by this paper
• Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110)

  2012cited by this paper
• Turning Receptors On and Off with Intracellular Pepducins: New Insights into G-protein-coupled Receptor Drug Development*

  2012cited by this paper
• Targeting proteinase-activated receptors: therapeutic potential and challenges

  2012cited by this paper
• Modulation of PAR1 signalling by benzimidazole compounds

  2012cited by this paper
• Protease‐activated receptor‐1 cleaved at R46 mediates cytoprotective effects

  2012cited by this paper
• Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46.

  2012cited by this paper
• Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor

  2012cited by this paper
• Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1

  2011cited by this paper
• Protease-activated receptor 2 signaling in inflammation

  2011cited by this paper
• Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through β-arrestin and dishevelled-2 scaffolds

  2011cited by this paper
• Structure, function and pathophysiology of protease activated receptors.

  2011cited by this paper
• Activated Protein C N-Linked Glycans Modulate Cytoprotective Signaling Function on Endothelial Cells*

  2010cited by this paper
• Novel agonists and antagonists for human protease activated receptor 2.

  2010cited by this paper
• Improved synthesis of the PAR-1 thrombine receptor antagonist RWJ-58259

  2009cited by this paper
• Cu-catalyzed azide-alkyne cycloaddition.

  2008cited by this paper
• Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

  2008cited by this paper
• Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C

  2007cited by this paper
• The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells.

  2007cited by this paper
• Rapid functional assays of intracellular Ca2+ channels

  2006cited by this paper
• Protease‐activated receptors‐1 and ‐2 can mediate endothelial barrier protection: role in factor Xa signaling

  2005cited by this paper
• An Offline-Addition Format for Identifying GPCR Modulators by Screening 384-Well Mixed Compounds in the FLIPR

  2005cited by this paper
• High-affinity thrombin receptor (PAR-1) ligands: a new generation of indole-based peptide mimetic antagonists with a basic amine at the C-terminus.

  2003cited by this paper
• Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective

  2003cited by this paper
• Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates

  2003cited by this paper
• Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1.

  2003cited by this paper
• Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

  2002cited by this paper
• Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.

  2001cited by this paper
• Thrombin signalling and protease-activated receptors

  2000cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper
• Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor.

  1999cited by this paper
• A permanent human cell line (EA.hy926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells.

  1995cited by this paper
• Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor.

  1994cited by this paper
• Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.

  1991cited by this paper
• A non-disruptive technique for loading calcium buffers and indicators into cells

  1981cited by this paper

• Novel Function for Endothelial Protease-Activated Receptors in Modulating Insulin Receptor Activity With Implications for Diabetes

  2025cites this paper
• INFLUENCE OF DIFFERENT TYPES OF ALLOSTERIC REGULATORS ON THE BASAL AND HORMONE-STIMULATED ACTIVITY OF THE THYROID-STIMULATED HORMONE RECEPTOR IN VITRO AND IN VIVO

  2025cites this paper
• Characterizing Modulators of Protease-activated Receptors with a Calcium Mobilization Assay Using a Plate Reader.

  2024cites this paper
• Hormonal and Allosteric Regulation of the Luteinizing Hormone/Chorionic Gonadotropin Receptor.

  2024cites this paper
• THE NEUROENDOTHELIAL AXIS IN TRAUMATIC BRAIN INJURY: MECHANISMS OF MULTIORGAN DYSFUNCTION, NOVEL THERAPIES, AND FUTURE DIRECTIONS

  2024cites this paper
• Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands

  2023cites this paper
• Targeting biased signaling by PAR1: function and molecular mechanism of parmodulins

  2023cites this paper
• Induction of endothelial barrier dysfunction by serum factors in rats subjected to traumatic brain injury and hemorrhagic shock

  2022cites this paper
• Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression

  2022cites this paper
• Q94 is not a selective modulator of proteinase-activated receptor 1 (PAR1) in platelets

  2022cites this paper
• Plasmonic Imaging of Dynamic Interactions between Membrane Receptor Clusters beyond the Diffraction Limit in Live Cells.

  2021cites this paper
• Reversal of the renal hyperglycemic memory by targeting sustained tubular p21 expression

  2021cites this paper
• Research on the Influence of Electrified Railway Interference on Outdoor Signals Based on Computer Simulation Analysis under High Speed Rail and Heavy Load Conditions

  2020cites this paper
• Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2.

  2020cites this paper
• Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches

  2020cites this paper
• The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability.

  2019cites this paper
• Synthesis and Initial Pharmacology of Heterobivalent Ligands Targeting Putative Complexes of Integrin αVβ3 and PAR2

  2019cites this paper
• Amyloid peptides and the vascular system : the link between cerebrovascular angiopathy and Alzheimer's disease

  2019cites this paper
• Design and Evaluation of Heterobivalent PAR1-PAR2 Ligands as Antagonists of Calcium Mobilization.

  2018influential citation
• Arteriosclerosis, Thrombosis, and Vascular Biology

  year unknowninfluential citation